Assessment Of Pharmacist Intervention On Depression Patients' Adherence And Clinical Outcomes In A Tertiary Care Centre At Riyadh, Saudi Arabia by Al-Jumah, Khalaf Ali
  
  
ASSESSMENT OF PHARMACIST 
INTERVENTION ON DEPRESSION PATIENTS' 
ADHERENCE AND CLINICAL OUTCOMES IN A 
TERTIARY CARE CENTRE AT RIYADH, SAUDI 
ARABIA 
  
 
 
 
 
 
 
KHALAF ALI AL-JUMAH 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2016  
  
 
  
    
 
ASSESSMENT OF PHARMACIST INTERVENTION ON DEPRESSION 
PATIENTS' ADHERENCE AND CLINICAL OUTCOMES IN A 
TERTIARY CARE CENTRE AT RIYADH, SAUDI ARABIA 
 
 
 
 
by 
 
 
 
 
 
KHALAF ALI AL-JUMAH 
 
 
 
 
   Thesis submitted in fulfilment of the requirements  
For the Degree of  
Doctor of Philosophy    
 
 
 
 
July 2016 
  
    
 
  
  i 
DEDICATION 
 
I would like to acknowledge and dedicate this thesis to my parents for their support 
throughout my education and to my wife and kids, who tolerated much for my own 
benefit and success. I would like to thank you for all of your support and 
encouragement throughout my thesis work. God bless you all and I thank God for all 
of my achievements. I pray to God to accept my modest achievements and consider 
them as good deeds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  ii 
ACKNOWLEDGEMENT 
       In the name of ALLAH who taught man about matters that he does not knows 
and prayers and peace be upon our holy prophet Mohammad the last of all God‘s 
prophets and his good followers till the day of judgment. First of all I thank ALLAH 
Subhanahu Wa Ta'ala, He who has helped and guided me throughout my life. 
    I would like to thank the School of Pharmaceutical Sciences, Universiti Sains 
Malaysia (USM) for giving me this opportunity to pursue my postgraduate studies in 
the Discipline of Social and Administrative Pharmacy (DSAP). I wish to take this 
opportunity to thank the faculty members and staff of DSAP for their kind help, 
especially the head of the Discipline Assoc. Prof. Dr. Asrul Akmal Shafie. 
My deep appreciation also goes to my main supervisor, Professor Dr. 
Mohamed Azmi Bin Ahmad Hassali who spared no efforts to guide me on 
throughout my PhD research project and thesis writing. Indeed, I am very honoured 
and lucky to work under his distinguished supervision, to learn the ideal scientific 
approaches to solve research problems starting from the early phase (formulation of 
research questions, literature review) all the way through the selection of 
methodology, analysis of the results and writing the thesis. I greatly appreciate his 
calm and tolerance to me and my endless questions and untimed discussions. I pray 
for God to convey upon him peace of mind, health and happiness throughout his life. 
I also wish to thank my field supervisor Professor Dr. Kamal El Din Hussein El 
Tahir, professor of pharmacology at College of Pharmacy, King Saud University for 
his help, support and supervision during the field work and data collection. To him 
may Allah bestow the peace of mind, good health, and happiness. I also wish to 
express my sincere gratitude to the staff of Al-Amal hospital for mental health, 
  
  iii 
Riyadh Saudi Arabia for their help and support. To the staff in the School of 
Pharmacy, I cannot thank them enough for their help and support. 
    Last but not least, I would like to acknowledge all my colleagues, especially 
Ibrahim Al-Aboudi and Alian Alrasheedy for their support, and help during my 
postgraduate study and for the whole of my stay in Malaysia.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  iv 
 
TABLE OF CONTENTS 
 
    
 
 
Acknowledgement  ii 
 
Table of Contents iv 
 
List of Tables x 
 
List of Figures xiii 
 
List of Abbreviations xiv 
 
Abstrak xv 
 
Abstract xviii 
CHAPTER 1: GENERAL INTRODUCTION   
1.1  Health Care System in Saudi Arabia 1 
 
1.2  Mental Health Services  3 
 
1.3  Role of Pharmacist in Mental Health Care System  5 
 
1.4  Future Plan for Mental Health Care System  6  
 
1.5  Depression  6 
 
1.6  Treatment of Depression   7 
 
1.7  Adherence to Antidepressants 8 
 
1.8  Shared Decision Making 11 
  
1.9  Characteristics of Shared Decision Making 13 
 
1.10  Steps for Shared Decision Making 14 
 
1.11  Patients Participate in Shared Decision Making 15 
 
1.12  Decision Aids  16 
 
1.13  Factors Influencing Shared Decision Making 17 
 
    
  
  v 
 
1.14  Barriers in the Implementation of Shared Decision Making 17 
 
1.15  Intervention Design According to Shared Decision Making 18 
 
1.16  Theoretical Explanation for Medication Adherence 18 
 
1.17  Patients Beliefs about Antidepressants and Adherence 20 
 
1.18  Research Problems  22 
 
1.19  Justification of the Study 23 
 
1.20  Importance of the Study 24 
  
1.21  Research Aim, Objective, and Question 25 
  
1.22  Overview of Thesis   27 
CHAPTER 2: LITERATURE REVIEW  
2.1  Introduction   29 
 
2.2  Consequences of Non-Adherence 31 
 
2.3  Adherence Measurement  32 
 
2.4  Barriers to Adherence 33 
 
2.5  Factors Affecting Adherence to Medication in Saudi Arabia  35 
 
2.5.1  Social and Economic Factors 35 
 
2.5.2  Healthcare System-Related Factors 36 
 
2.5.3  Condition-Related Factors 37 
 
2.5.4  Therapy-Related Factors 38 
 
2.5.5  Patient-Related Factors  39 
 
2.6  Adherence Enhancing Outcome  40 
 
2.7   Interventions to Improve Adherence to the Antidepressants  40 
 
2.8  Treatment Satisfaction Toward Antidepressants 42 
 
 
 
 
    
  
  vi 
 
2.9   Health-Related Quality of Life   43 
 
2.10  Pharmacist Intervention 45 
  
2.11  Patients and Pharmacists Discussing Medication  45 
 
2.12  Impact of pharmacist intervention on adherence and Patients  
 Reported Outcome Among Depressed Patients  46 
  
 
CHAPTER 3: PRE-INTERVENTION AND INTERVENTION STUDY METHODOLOGY 
 
Introduction  55 
 
3.1  Pre-intervention Phase 56 
 
3.1.2  Cross-Sectional Study Types 57 
 
3.1.2.1 Descriptive Cross-Sectional Study  57 
 
3.1.2.2 Analytical cross-sectional study  57 
 
3.1.3  Sample Selection and Response Rates in Cross-Sectional Studies 57 
 
3.1.4 Data Collection 58 
 
3.1.5  Data Analysis 58 
 
3.1.6  Outcome and Exposure Measures 59 
 
3.1.7  Cross-sectional Studies Sample Size  59 
   
3.1.8  Objective of the Cross-Sectional Study 60 
  
3.1.9  Cross-Sectional Study Methodology 60 
 
3.1.10  Study Design  61 
 
3.1.11  Study Setting  61 
 
3.1.12  Patient Populations 61 
 
3.1.13  Sample Size 62 
 
3.1.14  Research Instruments  63 
 
 
   
                                                                                                                            
  
  vii 
 
3.1.15  Validity  63  
 
3.1.16  Ethical Considerations 64 
 
3.1.17  Study Variables and Data Collection Procedures  65 
 
3.1.18  Data Analysis    67 
 
3.2  Intervention Phase   68 
 
3.2.1  Aim 70 
 
3.2.2  Objectives  70 
 
3.2.3  Settings   71 
 
3.2.4  Patient Populations 72 
 
3.2.5  Sample Size  73 
 
3.2.6  Study Variables  73 
 
3.2.7  Assessment of Adherence to Antidepressant Medication  74 
 
3.2.8  Assessment of Patients Beliefs about Medication 75 
 
3.2.9  Assessment of Severity of Depression  75 
 
3.2.10  Assessment of Patients Involvement in Decisions 76 
 
3.2.11  Assessment of Health-Related Quality of Life 77 
 
3.2.12  Assessment of Patient Satisfaction to Treatment  77 
  
3.2.13  Developing and Implementation of Shared Decision Making 78 
 
3.2.14  Training Program Validity       78 
      
3.2.15  Overview of Training Program  78 
 
3.2.15.1       First Section: General Introduction to 
                    Patient-Centred Care 80 
 
3.2.15.2       Second Section: Training Pharmacists About  
         Pharmacotherapy of Depression and How to  
         Effectively Use Decision Aids 81 
 
 
    
  
  viii 
 
3.2.15.3 Third section: Training on SDM Skills and Competency  82 
 
3.2.16 Overview of the Interventional Program (Shared  
 Decision Making) 83 
 
3.2.17  Decision Aid 84 
 
3.2.18  Translation and Validation of Decision Aid 86 
 
3.2.19  Randomization and Allocation  88 
 
3.2.20  Data Collection and Analysis  89 
 
3.2.21  Dropouts 90 
 
3.2.22  Ethical Approval 90  
CHAPTER 4:  DEVELOPMENT AND VALIDATION OF DECISION  
 AID FOR DEPRESSED PATIENTS 
4.1  Introduction  92 
 
4.2  Methods  92 
 
4.3  Sample Size and Statistical Analysis 93 
 
4.4  Ethical Consideration  93 
 
4.5  Development of Decision Aid 93 
 
4.6   Measuring Involving Patients in Decisions Making 94 
 
4.7  Results 95 
 
4.7.1   Decision Aid (DA)  95 
 
4.7.2  Involvement in Decisions 96 
 
4.8  Discussion 100 
 
4.9  Conclusion  102 
 
 
 
 
  
  ix 
  
CHAPTER 5: FINDINGS AND DISCUSSION OF PRE-INTERVENTION 
PHASE  
    
5.1  Introduction  103 
   
5.2  Results of Pre-Intervention Study 104 
 
5.3 Discussion 138 
 
5.3.1  Predictors of Adherence to Medication  138 
 
5.3.2  Relationship Between Adherence and Treatment  
 Satisfaction  142 
    
5.3.3   Relationship Between Adherence And health related  
 quality of life  145  
CHAPTER 6: FINDINGS AND DISCUSSION OF INTERVENTION PHASE  
6.1  Introduction  148 
 
6.2  Results  150 
  
6.3  Discussion 160  
CHAPTER 7: THESIS CONCLUSION AND RECOMMENDATION 
 
7.1  Introduction  166 
 
7.2  Conclusion for the Pre-Intervention Phase (Cross-Sectional Study)  167 
 
7.3  Conclusion for Pilot Study 168 
 
7.4  Conclusion for the Intervention Phase: Randomized Control Study 169 
 
7.5  Recommendations  171 
 
7.5.1  General Recommendations for Healthcare Providers  171 
 
7.5.2  Recommendations for Future Studies  172  
 
REFERENCES      173 
APPENDICES    194 
GLOSSARY OF KEY TERMS   
LIST OF PUBLICATIONS 
 
 
  
  x 
 
                                    LIST OF TABLES                                     
                                                                                                        Page 
 
Table 1.1  Competency Framework for Shared Decision-Making 15 
 
Table 2.1  Advantages and Disadvantages of Adherence Measuring  
 Methods   33 
 
Table 2.2  Impact of Pharmacist Intervention on Adherence  49 
 
Table 2.3  Impact of Pharmacist Intervention on Patient Reported  
 Outcome  and Depression 52 
 
Table 3.1  Summary of Questionnaire and Scale Validation  64 
 
Table 3.2  Measures and Data Collection Schedules  91 
 
Table 4.1        Expert Evaluations of the Decision Aid Based On the  
                       International Patient Decision Aid Checklist                              96 
 
Table 4.2  Demographic Characteristics Of Study Participants  97 
 
Table 4.3  Difference in Observing Patient Involvement in Decision  
 Making Scale Score Between the Controlled Group  
 and Intervention Group 98 
 
Table 4.4  Satisfaction Level Differences According to Observing  
                       Patient Involvement in Decision Making Scale Score 
                       Between the Controlled Group and Intervention Group 99 
 
Table 5.1  Characteristics of Study Participants and their Adherence  
 Level 105 
 
Table 5.2  Participants‘ Reported Adherence Behavior by MMAS-8 107 
 
Table 5.3  T-test Investigating Difference According to Gender 109 
 
Table 5.4  One Way Analysis of Variance (F-test) Investigating Difference  
 According to Age 110 
 
Table 5.5  Multiple Range Tests (Scheffe test) Investigating 
                       Difference According to the Age 112 
 
Table 5.6  One Way Analysis of Variance (F-test) Investigating  
                       Difference According to the Education Level 114 
 
Table 5.7  Multiple Range Tests (Scheffe Test) Investigating  
                       Difference According to the Education Level 116 
 
  
  xi 
 
    
 
Table 5.8  T-test Investigating Difference According to the Number of 
Antidepressant Drugs Currently Taken  117 
 
Table 5.9  One Way Analysis of Variance (F-test) Investigating Difference  
 According to the Type of Antidepressant Drugs  
                       Currently Taken  119 
 
Table 5.10  Multiple Range Tests: Scheffe Test Investigating Difference in  
 According to the Type of  Antidepressant Drugs 
                       Currently Taken  120 
 
Table 5.11  One Way Analysis of Variance (F-test) Investigating Difference  
 According to the Number of  Clinic Visit per Year  122 
 
Table 5.12  Multiple Range Tests (Scheffe Test) Investigating 
                       Difference According to the Number of Clinic Visit    123 
 
Table 5.13 One Way Analysis of Variance (F-test) Investigating  
                       Difference According to the Illness Duratio 125 
 
Table 5.14  Multiple Range Tests (Scheffe Test Investigating 
                       Difference  According to the Illness Duration  126 
 
Table 5.15  Patients‘ Beliefs Regarding Antidepressants, the  
 Severity of Their Depression and Their Level of Adherence 127 
 
Table 5.16  Multiple Regression (Stepwise Method) Analysis Of The 
                       Characteristics Influencing Adherence (Model Summary) 128 
 
Table 5.17  Study Participants Characteristics and Level of  
                       Treatment Satisfaction  129 
 
Table 5.18  Patient Satisfaction Regarding Antidepressant and Level  
 of Adherence 130 
 
Table 5.19  Pearson Correlation Coefficients Between the  
 Factors of the Treatment Satisfaction Questionnaire  
 for Medication and Level of Adherence and Patient Beliefs.  131 
 
Table 5.20  Demographic Characteristics and HRQoL  
 Characteristics  132 
 
Table 5.21  Frequency of Self-Reported (EQ-5D) Health States 133 
  
Table 5.22  Correlation Coefficient for Total Adherence, Severity  
 of Depression, and EQ-5D – EQ-VAS Scores) 135 
 
  
  xii 
 
    
 
Table 6.1  Patients Demographic Characteristic by Groups  152 
 
Table 6.3  T-test Investigating Difference According to the Level 
                        of Adherence  153 
 
Table 6.3  T-test Investigating Difference According to the Level 
                        of Adherence (After the Second Reading)  154 
 
Table 6.4  T-test Investigating Difference According to the Level 
                        of Adherence (After the Third Reading)  155 
 
Table 6.5  T-test: Paired Samples test Investigating Difference 
                        Between the pre-reading & Second Reading  
                       (Experimental Group) 156 
 
Table 6.6  T-test: Paired Samples Test Investigating Difference 
                       Between the Pre-Reading & Third Reading 
                       (Experimental Group)  157 
 
Table 6.7  T-test: Paired samples test Investigating difference 
                        Between the pre-reading & Third Reading  
                        (Experimental Group)  158 
 
Table 6.8  T-test: Paired samples test Investigating difference in level  
 of OPTION scores between the pre-reading &  
 second reading (Experimental group) 159 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
  xiii 
LIST OF FIGURES 
                                                                                                               Page  
 
Figure 3.1   Study design                                                                               74 
Figure 6.1  Study flow diagram      151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  xiv 
 LIST OF ABBREVIATIONS 
 
BMQ Beliefs About Medicine Questionnaire  
CG Control Group 
CSS Cross Sectional Study  
DA Decision Aids  
IG Intervention  group  
MADRAS Montgomery–Åsberg Depression Rating Scale 
MAQ Medication Adherence Questionnaire  
MDD Major Depressive Disorder 
MMAS Morisky Medication Adherence Scale 
MOH Ministry of Health  
MRC Medical Research Council  
NIH National Institutes of Health 
NPC National Prescribing Centre 
OPTION Observing Patient Involvement in decision 
PDA Patent Ductus Arteriosus  
PIS Participant Information Sheet  
QOL Quality of life 
RCT Randomized Controlled Trial 
SDM Shared Decision Making  
TSQM Treatment Satisfaction Questionnaire for Medication 
WHO World Health Organization 
 
  
  xv 
PENILAIAN INTERVENSI AHLI FARMASI KE ATAS KEPATUHAN 
MEMAKAN UBAT DAN KESAN KLINIKAL PESAKIT MURUNG DI 
SEBUAH PUSAT PENJAGAAN TERTIER DI RIYADH, ARAB SAUDI 
                                         
ABSTRAK 
Kemurungan atau depresi merupakan penyakit mental kronik yang 
mempunyai kesan yang boleh menimbulkan ketidakupayaan yang signifikan 
terhadap kualiti hidup pesakit. Prevalens kemurungan mencecah 15% di seluruh 
dunia dan 18% di Arab Saudi. Secara am, ubat antikemurungan menjadi kurang 
berkesan kerana ketidakpatuhan pesakit dalam pengambilan ubat. Hal ini boleh 
menyebabkan akibat yang serius seperti kegagalan rawatan, komplikasi, penggunaan 
penjagaan perubatan yang tinggi, dan kerosakan tubuh sehingga tidak berupaya 
melakukan sesuatu kerja. Peranan ahli farmasi dalam sistem penjagaan kesihatan kini 
menjadi lebih luas sehingga meliputi kerja-kerja ujian klinik, ekonomi kesihatan, 
pendidikan pesakit, dan penjagaan pesakit secara langsung. Intervensi ahli farmasi 
terbukti dapat memberi manfaat dalam usaha meningkatkan hasil rawatan dalam 
pelbagai keadaan penjagaan kesihatan. Justeru, projek penyelidikan ini bertujuan 
untuk menilai impak intervensi ahli farmasi yang berdasarkan perkongsian 
pembuatan keputusan bagi memperbaiki tahap kepatuhan mengambil ubat 
antimurung dan hal-hal yang berkaitan dengan kesan pada pesakit. Satu kajian 
keratan rentas analisis deskriptif telah dijalankan untuk memerihalkan populasi Saudi 
yang mengalami kemurungan berhubung dengan kepatuhan pengambilan ubat 
antimurung dan untuk menentukan faktor-faktor risiko dan hubungan antara 
kepatuhan dengan kesan-kesan berkaitan pesakit yang lain. Selepas itu, satu kajian 
rawak terkawal prospektif, dengan kajian susulan 6 bulan, telah dijalankan untuk 
menilai impak intervensi ahli farmasi. Satu kajian rentas telah dijalankan ke atas 403 
  
  xvi 
orang pesakit. Keputusannya. menunjukkan bahawa 52.9% pesakit tersebut telah 
melaporkan kepatuhan rendah dalam pengambilan ubat antimurung dan purata skor 
skala kepatuhan ubat Morisky (5.23 daripada 8) dengan perbezaan signifikan secara 
statistik dalam tahap kepatuhan memihak kepada pesakit lelaki, pesakit yang 
berumur lebih tua, pesakit yang mengalami tempoh sakit yang lebih pendek, dan 
mereka yang membuat lawatan susulan lebih daripada tiga kali setahun di klinik 
psikiatri. Tentang peramal kepatuhan pengambilan ubat antimurung, keputusannya 
menunjukkan  bahawa kepercayaan  bimbang (R = 0.40; P <  .001;  R2 = 0.162) 
merupakan peramal terpenting bagi kepatuhan pengambilan ubat antimurung. Dalam 
kajian rawak terkawal yang dijalankan, 239 pesakit yang memenuhi kriteria sampel 
telah ditetapkan ke dalam kumpulan intervensi (n = 119) dan kumpulan kawalan (n = 
120). Bagaimanapun, 19 orang pesakit  telah menarik diri daripada kajian ketika 
dalam fasa susulan.  Selepas 6 bulan, pesakit dalam kumpulan intervensi telah 
menunjukkan perbezaan yang signifikan secara statistik dalam kepatuhan 
pengambilan ubat, berpuas hati dengan rawatan, percaya bahawa secara amnya 
mereka lebih memakan ubat, kepercayaan bimbang khusus dan secara am lebih 
percaya tentang ubat berbanding dengan mereka yang di dalam kumpulan kawalan. 
Bagaimanapun, perbezaan signifikan secara statistik tidak dikesan antara kedua-dua 
kumpulan dari segi teruknya kemurungan dan kesihatan yang berkait dengan kualiti 
hidup. Sebagai kesimpulan, intervensi ahli farmasi yang berasaskan perkongsian 
membuat keputusan dengan pesakit yang menghadapi kemurungan menunjukkan 
penambahbaikan yang signifikan dari segi kepatuhan makan ubat, kepuasan terhadap 
rawatan, dan kepercayaan pesakit terhadap ubat antimurung apabila dibandingkan 
dengan penjagaan biasa. Oleh itu, dapatan ini menyarankan bahawa peranan ahli 
farmasi boleh dikembangkan bagi menyediakan penjagaan pesakit secara langsung 
  
  xvii 
dalam amalan psikiatri dan dalam amalan farmasi biasa untuk menambah baik 
kepatuhan pesakit memakan ubat dan mengatasi kesan pesakit yang lain yang pernah 
dilaporkan. 
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ASSESSMENT OF PHARMACIST INTERVENTION ON DEPRESSION 
PATIENTS' ADHERENCE AND CLINICAL OUTCOMES IN A TERTIARY 
CARE CENTRE AT RIYADH SAUDI ARABIA 
 
ABSTRACT  
Depression is a chronic mental illness with a significant disabling effect on 
the patient‘s quality of life. Depression lifetime prevalence reach up to 15% 
worldwide and up to 18% in Saudi Arabia. In general the effectiveness of 
antidepressants is reduced due to patients‘ non-adherence. This may result in serious 
consequences such as treatment failure, complications, high medical care utilization, 
and impairment in work functioning. The role of pharmacists in the healthcare 
system has expanded to include involvement in clinical trials, health economics, 
patient education, and direct patient care. Pharmacist interventions have proved to be 
beneficial in improving treatment outcomes in a variety of healthcare settings. 
Therefore, this research aims to evaluate the impact of a pharmacist intervention 
based on shared decision making to improve adherence to antidepressant medication 
and related patient outcomes. A cross-sectional descriptive analysis study was carried 
to describe depressed Saudi population with respect to adherence to antidepressant 
and to determine the risk factors and the association between adherence and other 
patient-related outcomes. Then, a prospective randomized controlled study, with six-
month follow-up, was conducted to evaluate the impact of pharmacist intervention. A 
cross-sectional study was conducted on 403 patients. The result showed that 52.9% 
of the patients reported low adherence to antidepressant medication and average 
Morisky medication adherence scale score (5.23 out of 8) with statistically 
significant differences in adherence level in favour of males, older patients, patients 
with a shorter duration of illness, and those having more than three follow-up visits 
  
  xix 
with a psychiatric clinic per year. Regarding the predictors of adherence to 
antidepressant, the result showed that the concerns beliefs (R = 0.40; P < .001 R2 = 
0.162) was the most important predictor associated with adherence to 
antidepressants. In the randomized controlled study, 239 patients met the inclusion 
criteria and were assigned to the intervention group (n = 119) and the control group 
(n = 120). However, 19 patients dropped out of the study during the follow-up phase. 
After 6 months, patients in the intervention group showed statistically significant 
differences in adherence to medication, treatment satisfaction, general overuse 
beliefs, specific concerns beliefs and the total general beliefs about medicines 
compared with those in the control group. However, no statistically significant 
difference was observed between the two groups in terms of severity of depression 
and health-related quality of life. In conclusion, pharmacist intervention based on 
shared decision making with depressed patients showed a significant improvement in 
adherence, treatment satisfaction and patients‘ belief of antidepressants compared 
with patients having the usual care. Thus, this finding suggests that the pharmacist 
role can be enhanced to provide direct patient care in psychiatric and in regular 
pharmacy practice to improve adherence to medication and other patients reported 
outcomes 
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CHAPTER ONE 
General introduction 
1.1 The health care system in Saudi Arabia 
 The healthcare system in Saudi Arabia has improved significantly in the last four 
decades (Almalki et al., 2011, Walston et al., 2007). In 2005, the World Health 
Organization (WHO) had ranked the Saudi healthcare system at 26
th
 compared to 
190 other health systems worldwide (WHO, 2005). The Saudi population reached 
29.1 million in 2013, with a high annual population growth rate and fertility rate 
(3.19 % and 2.87 % annually, respectively). Approximately half of the population 
(50.2%) are males and 49.8% are females; 33 % of the population is younger than 15 
years of age, 2.7% of the population is over 65 years old, and the life expectancy is 
73.8 years (Almalki et al., 2011, Amir, 2012, MOH, 2013).   
Article number 31 of the Saudi constitution states that ―the government provides all 
citizens and expatriates working within the public sector with full and free access to 
all public health care services". Additionally, Article number 27 states that ―The 
government is responsible for caring for the citizen and his family in case of 
emergency, illness, disabilities and during old age‖ (Almalki et al., 2011, Jannadi et 
al., 2008). 
The Saudi government increases the budget of the Ministry of Health (MOH) 
annually. Allocations to the MOH from the government general budget have steadily 
increased over the years from 800,000,000 $ (representing 2.8% of the total 
government budget) in 1970 to 20,400,000,000 $ (representing 6.8%) in 2013, which 
represents 680 $ per citizen per year (MOH, 2013).    
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The MOH provides health services at three levels: primary, secondary and tertiary 
(Almalki et al., 2011, MOH, 2013). Primary care services are provided through 
primary health care centres (PHCCs) that are distributed throughout the country to 
provide preventive services, vaccinations, curative services, maternity care, 
paediatric care and chronic disease follow-up. Moreover, via the referral system, the 
primary care system refers the cases that require more advanced care and 
intervention to the general hospitals (secondary level) or specialized hospitals 
(tertiary level) (Almalki et al., 2011, MOH, 2013). 
The MOH is the major provider of healthcare services, with a total of 259 hospitals 
(35,828 beds) and 2,250 PHCCs (Almalki et al., 2011, Amir, 2012, MOH, 2013). 
The MOH provides health care services at a rate of 24.4 physicians per 10,000 
citizens, 47.8 nurses per 10,000 citizens and 5.3 pharmacists per 10,000 citizens 
(MOH, 2013). Furthermore, the private sector also provides health care services, 
with a total of 137 hospitals (14,165 beds) and 2,366 dispensaries and clinics (MOH, 
2013). 
The healthcare system in Saudi Arabia is facing several challenges, ranging from the 
development of health care service to the population growth, particularly in the 
elderly and as a result of the high fertility rates amongst the Saudi population; this 
also increases the demand for social services including health care (Almalki et al., 
2011, Al Yousuf et al., 2002, MOH, 2013). Another challenge facing the healthcare 
system in Saudi Arabia is the rapid increase in the costs of healthcare services 
because of changes in public expectations and demands for high quality services 
(Almalki et al., 2011, Al Yousuf et al., 2002, MOH, 2013). In general, increasing 
services leads to increased demands for health manpower, which includes 
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pharmacists; however, the medical staff is experiencing a shortage in Saudi Arabia 
(MOH, 2013). Another challenge facing the healthcare system in Saudi Arabia is the 
increase in the prevalence of chronic diseases (hypertension, diabetes, chronic heart 
disease, mental health and cancer) as a result of modernization and changes in 
lifestyle (MOH, 2013). There is also a shortage of hospital beds and an 
overwhelming demand for inpatient services for mental health patients (Koenig et al., 
2014). Finally, the lack of information and prevalence studies about mental health in 
the general population in Saudi Arabia represents an important challenge facing all 
healthcare providers working in psychiatric hospitals (Koenig et al., 2014).‎ 
1.2 Mental health services  
As part of the progress in the healthcare system in Saudi Arabia, the identification 
and treatment of mental health disorders over the last three decades has improved 
significantly (Qureshi et al., 2013). Currently, mental health care services are 
provided through 25 specialized hospitals compared to only one such mental hospital 
30 years ago (Shehar mental hospital) that served the entire population of Saudi 
Arabia (Dubovsky, 1983, Koenig et al., 2014). The mental health expenditure is 
reported as 640,000,000 $ (Qureshi et al., 2013).   
The MOH provides free mental health services to the public in Saudi Arabia through 
twenty-five mental hospitals, corresponding to 12 beds per 100,000 citizens (MOH, 
2013). The admission rate in psychiatric hospitals is 1.92 per 100,000 citizens per 
year. The predominant diagnoses of patients admitted to psychiatric hospitals are 
schizophrenia (50%), substance-abuse disorders (20%), and mood disorders (20%). 
The average length of hospitalization is 45 days (Qureshi et al., 2013). 
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The MOH also provides mental health services through 94 public outpatient clinics. 
Of these, 20 clinics are specialized in child psychiatry and are located in non-
psychiatric hospitals. The outpatient clinics treat approximately 1,846 patients per 
100,000 citizens per year. Six percent of individuals seen in outpatient clinics are 
children and adolescents. Patients treated in outpatient facilities are most frequently 
diagnosed with mood disorders (35%), neurotic, stress-related, or somatoform 
disorders (36%), schizophrenia (13%), substance abuse (9%), personality disorders 
(2%), and others (5%) (MOH, 2013, Qureshi et al., 2013). Patients with an identified 
psychiatric problem in Saudi Arabia have an average of 3 outpatient visits per year 
(Qureshi et al., 2013). 
In 2013, the Saudi government passed a Mental Health Act (MHA) that aimed to 
achieve the following purposes: "(1) improving access to mental healthcare 
generally, (2) ensuring the least restrictive level of care, (3) preserving the rights of 
patients, family members, and other caregivers, (4) streamlining competence, 
capacity, and guardianship issues, including voluntary and involuntary treatment, (5) 
ensuring the accreditation of professionals and facilities, (6) enforcing mental health 
laws and other legal issues, and (7) establishing mechanisms to implement these 
provisions" (Qureshi et al., 2013, Koenig et al., 2014). 
Mental health research has increased slowly over the past decades in Saudi Arabia; 
there were no published studies before 1975 whereas a limited number of studies 
have been published during the last decade (Dubovsky, 1983, Jaalouk et al., 2012). 
Moreover, although the annual publication rate increased in Saudi Arabia from 0 - 1 
between 1966 and 1985 to 18 between 1996 and 2006, there remains a huge gap 
between the research situation in Saudi Arabia and that in Western countries (Jaalouk 
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et al., 2012, Koenig et al., 2014). Until now, no studies have investigated the 
prevalence of mental disorders in the general Saudi population despite the fact that 
this information is essential to improve mental health services in Saudi Arabia 
(Koenig et al., 2014). 
1.3 Role of pharmacists in the mental health care system  
Recently, experts and organizations such as the WHO have supported the increased 
role of pharmacists in the care of mentally ill patients (Al-Aqeel et al., 2012, 
Everard, 2005). In Saudi Arabia, out of 2,293 pharmacists and 6,619 pharmacy 
technicians working in the MOH, only 89 pharmacists and 197 pharmacy technicians 
work in mental health services (representing 3.8% of pharmacists and 2.9% of 
pharmacy technicians working in the MOH) (MOH, 2013). 
Al-Aqeel et al., 2012 investigated the experience and future expectations of 
psychiatrists with pharmacists in mental health services in Saudi Arabia. Overall, the 
study reported a positive experience and positive expectations. In total, 66% of the 
psychiatrists agreed that pharmacists are reliable sources of clinical drug information, 
65% thought that pharmacists should inform doctors if patients are experiencing 
some problems with their medications, and 62% of the psychiatrists agreed that 
pharmacists are willing to take personal responsibility for resolving drug related 
problems they have discovered. Moreover, 43% agreed that pharmacists routinely 
counsel patients about drugs, and 48% stated that pharmacists inform doctors about 
the most cost-effective alternative. Furthermore, 66% of the psychiatrists agreed that 
pharmacists should routinely adjust the drug therapy for patients under an approved 
protocol (Al-Aqeel et al., 2012). 
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1.4 Future plan for the mental healthcare system  
 The health authorities in Saudi Arabia have developed a comprehensive plan to 
improve the quality of services and to implement the best practices in this field. This 
is performed by seeking accreditation by the local accreditation body in Saudi Arabia 
and the international accreditation bodies. Simultaneously, efforts are increased to 
implement new policies, expand mental healthcare services in primary healthcare and 
update the therapeutic drugs policy and guidelines  (Al-Habeeb and Qureshi, 2010). 
However, based on an extensive literature review, the effect of these actions and 
plans on patient outcomes and adherenceis has yet to be studied because there are no 
published studies investigating the effect of health‎care system related factors on 
patient adherence to psychotropic medications in ‎Saudi Arabia.‎ 
1.5 Depression  
Depression is a major chronic illness that affects approximately 15% of the 
population worldwide (Hunot et al., 2007, Vergouwen et al., 2003, Kessler and 
Bromet, 2013). Depression is defined as "a mental illness that features low mood, a 
sense of guilt and worthless. Patients report feeling sad, having low energy, and low 
self-esteem; patients also report feeling hopeless and beginning to think of death if 
this feeling continues for a long time. Some patients suffer from losing interest in 
things that they usually enjoyed before" (Al-Qadhi et al., 2014). 
Depression is classified as mild, moderate, or severe according to the severity of 
symptoms. It can also be classified as unipolar depression or bipolar mood disorder 
according to a history of manic episodes (Burcusa and Iacono, 2007, WHO, 2012). 
All types of depression can be chronic if the depressive symptoms are present for 
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more than 12 months with relapse of disease. Relapses and recurrences are common 
with depression, particularly amongst non-adherent patients or patients with co-
morbidities. Moreover, the onset of the first episode and the number of depressive 
episodes can affect the outcome and increase the risk of relapse (Burcusa and Iacono, 
2007). 
The WHO reported that approximately 350 million people worldwide suffered from 
depression in 2012 (WHO, 2012). Moreover, major depression is estimated to be the 
second most disabling disease by 2020 (WHO, 2012). In Saudi Arabia, the 
prevalence of depression has been estimated in several studies to range from 12 to 
20%. The estimated prevalence differed in those studies because of differences in the 
study settings, populations included, age groups selected, times, and geographic 
locations (Abdelwahid and Al-Shahrani, 2011, Al-Khathami and Ogbeide, 2002, 
Becker et al., 2002, El‐Rufaie et al., 1988).  
The population in Saudi Arabia has several risk factors for depression, including an 
already high prevalence of depression, a growing population, and increased co-
morbidities due to chronic diseases and the stress of modernization (Hidaka, 2012). 
Based on a literature review, little is known about the disease, treatment outcomes 
and the cost of treatment. The effect of disease symptoms and the loss of productivity 
or a pharmacoeconomic evaluation of therapy available in Saudi Arabia have yet to 
be reported (Al-Qadhi et al., 2014). 
1.6 Treatment of depression  
There are two main treatment approaches for depression: psychotherapy and 
pharmacological treatments. Electroconvulsive therapy is a third option that can be 
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used only if the main options of therapy are contraindicated or if the patient is unable 
to tolerate them (Amsterdam and Hornig-Rohan, 1996, Trivedi et al., 2010). 
According to the severity of disease, the healthcare team will select one of the two 
options. In severe cases, the combination of both options can be used. Additionally, 
for moderate-to-severe depression, the healthcare team will recommend a 
combination of antidepressant medication and psychotherapy (Al-Harbi, 2012, 
Marques et al., 2012, WHO, 2012). The therapeutic response rate to antidepressant 
therapy has reached 70%. This high response rate is difficult to achieve with other 
therapeutic approaches except for electroconvulsive therapy. Non-responders may 
show treatment-resistant symptoms combined with other social disorder symptoms 
(Al-Harbi, 2012, Marques et al., 2012). 
1.7 Adherence to antidepressants 
Depression is usually misdiagnosed by physicians, resulting in 50 % of patients with 
depression left untreated worldwide; therefore, it is expected that the use of 
antidepressants and other treatment options will increase worldwide (Dijkstra et al., 
2008, WHO, 2003). Antidepressants improve depressive symptoms by up to 70% 
within one month compared to a 30% improvement in the placebo group. The only 
other type of therapy to reach this improvement rate is electroconvulsive therapy 
(Marques et al., 2012). Although antidepressants have been shown to be effective, 
many patients do not receive an adequate dosage for an adequate duration (Katon et 
al., 1992, Marques et al., 2012). Their effectiveness is further reduced because of 
non-adherence to the medication by the patients. A total of 28% of patients 
discontinue medication after one month, and between 44 and 52% of patients 
discontinue medication after three months (Hunot et al., 2007). This is consistent 
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with a study conducted by Viguera et al. (1998) that showed that it is not uncommon 
in clinical practice for depressed patients to discontinue taking their medication. A 
study conducted with 4,312 subjects showed that adherence rates dropped to 51% 
after 4 months of treatment and decreased further to 21% after 8 months (Sawada et 
al., 2009). Similar results were found in Finland in the Vantaa depression study, 
which reported that only half of patients adhere to medication for one year (Sawada 
et al., 2009). Likewise, Peveler et al. found a non-adherence rate of 34–58% (Peveler 
et al., 1999). This is supported by a study by Cantrell et al. in which non-adherence 
to antidepressant treatment reached 57% in patients (Cantrell et al., 2006). 
‎Chronic diseases, mental disorders, human immunodeficiency virus/acquired 
immunodeficiency syndrome and tuberculosis together represented 54% of the 
burden of all diseases worldwide in 2001 and will exceed 65% worldwide by 2020 
(WHO, 2003). The evidence has shown poor adherence to antidepressant 
medications amongst patients diagnosed with a major depressive disorder (Sabatâe, 
2003). Data from different sources support the view that adherence to antidepressant 
medication is a dynamic behaviour that can vary from early to late treatment stages 
(Remien et al., 2003). Insufficiently treated depression may lead to serious 
complications such as relapse, drug resistance, increased treatment costs, and 
impairments in daily functioning (Hunot et al., 2007). These, in turn, may lead to 
increased rates of morbidity and mortality (Demyttenaere and Haddad, 2000, Julius 
et al., 2009).   
Several methods have been used to improve adherence to antidepressants in patients 
with mental illnesses, and these methods have been well-studied ‎in the literature 
(DiMatteo, 2004, Loh et al., 2007). They include educational interventions directed 
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towards the patients and their families, cognitive-support, reinforcement techniques 
and drug monitoring or a combination of these methods. However, few studies have 
been conducted to evaluate the interventions aimed to improve the quality of the 
patient-healthcare provider communication process regarding treatment options to 
improve adherence to antidepressant medication (Loh et al., 2007). Patient 
involvement in the decision-making process is an important predictor of patient 
adherence to antidepressants (Dwight-Johnson et al., 2001, Loh et al., 2007). The 
involvement of patients in the treatment process is considered to be the cornerstone 
in enhancing adherence in depressive patients (Vergouwen et al., 2009). 
Shared decision-making (SDM) supports the hypothesis that a patient‘s participation 
in the treatment decision-making will result in improved adherence, satisfaction and 
improved clinical outcomes. This study will focus on pharmacists‘ interventions to 
improve the adherence of depressed patients to antidepressant medications based on 
the shared decision-making approach. The role of pharmacists in the health system 
has expanded beyond the dispensing function to include clinical trials, health 
economics, patient education, and other roles related to patient care (Rubio-Valera et 
al., 2009). Moreover, pharmacist interventions have been shown to be beneficial for 
improving treatment outcomes in a variety of healthcare settings (Al-Jumah and 
Qureshi, 2011, Hanlon and Artz, 2001). Additionally, because of their excellent 
position of having direct patient contact, accessibility and availability, pharmacists 
can help patients to address barriers to adherence (for example: concerns about 
adverse effects, increased duration of therapy, frequency of drug administration and 
pill burden) and incorporate interventions into the care of their patients through 
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several strategies such as patient education, drug monitoring and management of 
adverse reactions (Al-Jumah and Qureshi, 2011, Marques et al., 2012). 
In Saudi Arabia, the concept of SDM is still in the beginning stages. It was first 
introduced by AlFaleh (AlFaleh et al., 2011), who developed and applied SDM to 
select either indomethacin prophylaxis or symptomatic treatment of Patent Ductus 
Arteriosus (PDA) for extremely low birth weight infants. The study revealed an 
improvement in both knowledge and decisional conflict scales (AlFaleh et al., 2011). 
Additional research in Saudi Arabia is necessary to evaluate interventions based on 
the improvement of patient involvement in the treatment decision-making process. 
1.8 Shared Decision-Making  
Over the past two decades in the literature, significant efforts have been made to 
encourage the active participation of patients in the treatment process and in 
decisions about their medications. These efforts have led to progressive concepts 
such as shared decision making (SDM) and patient-centeredness to create a way in 
which the patients can be involved in the entire treatment process (Osterberg and 
Blaschke, 2005). Since the 1990s, there has been increasing interest in the decision-
making authority of the patient. Moreover, several terms have been used to explain 
patient participation in treatment choices including ‗informed decision-making‘, 
‗concordance‘ and ‗evidence-based patient choice‘. SDM sits in the middle between 
the two extremes of a traditional paternalistic model and an informed choice model 
(Godolphin, 2009). The most accurate definition of shared decision making is "that it 
is a two-way exchange of information, consultation and decision-making, where 
deliberation and decisions are made by both the healthcare professional and the 
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patient" (Elwyn et al., 2000, Godolphin, 2009). Patients will be more motivated to 
follow agreed prescriptions and therapeutic plans, and the healthcare professional 
will deal with the patient as a partner to make collaborative decisions about the 
treatment (Dwight-Johnson et al., 2001, Godolphin, 2009). Without this partnership, 
there is concern that there will be an increase in non-adherence to treatment (Brody 
et al., 1989, Godolphin, 2009, Wilson et al., 2010). 
A close and significant association between the patient‘s active participation in 
medical treatment and improvements in clinical outcomes was reported by Lewin 
and et al (Brody et al., 1989, Lewin et al., 2002). Similar results were found by 
Wilson and et al regarding asthma treatment and clinical outcomes (Wilson et al., 
2010). 
 A systematic review has shown that there is a positive relationship between patient 
participation in the decision-making process and outcome, satisfaction, and improved 
self-esteem for patients (Joosten et al., 2008). Generally, the evidence supports the 
benefits of patient-centred care (Murray et al., 2005) and decision aids to improve 
deliberative treatment decisions (Orlando and Meredith, 2002). Moreover, when 
patients have the chance to share their decisions about treatment, there is a decrease 
in the discontinuation rate (Drake et al., 2009).  
Research on SDM in psychiatry is at an early stage. However, several randomized 
controlled trials have supported its positive effects on patient reported outcomes. 
Drake et al reported positive outcomes regarding patient satisfaction compared to a 
control group two years after applying multiple shared decision-making sessions on 
patients diagnosed with schizophrenia (Drake et al., 2009). Similarly, Von Korff et 
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al. reported an improvement in adherence and depressive symptoms in depressed 
patients after applying multiple sessions of shared decision making at 3, 6, 9, and 12 
months (Von Korff et al., 2003).  
Positive associations have also been found between shared decision making and 
depressed patient satisfaction.  In fact, patients became more satisfied with their care 
and treatment after participating in their care decisions (Swanson et al., 2007). 
In a recent analysis of SDM models, three systematic reviews showed that the 
predominant models were based on the physician–patient relationship without the 
participation of other healthcare providers who have roles in the decision-making 
process. This finding indicates the need for a new approach to provide opportunities 
for other healthcare professionals to be involved in the SDM processes (Towle and 
Godolphin, 1999, Légaré et al., 2011). 
In patients with depression, factors that are associated with non-adherence to 
treatment have been identified, but few investigations have been conducted to 
evaluate interventions that enhance patient participation in the selection of treatment 
regimes. This is an important consideration for further investigation into improving 
the management of the depressed patient 
1.9 Characteristics of shared decision-making 
Specific characteristics have been defined to categorize the interaction between 
patient and healthcare professionals; these characteristics are continuous rather than 
dichotomous variables (Stacey et al., 2010). 
 Two parties are involved in shared decision-making. 
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 Both parties take steps to participate in the process of treatment decision-
making. 
 Sharing of information occurs by both parties in the process of shared decision-
making. 
 Both parties agree to whatever treatment decision is made. 
 
1.10 Steps for shared decision-making 
A competency framework is a collection of those competencies that are important to 
perform effectively. Competencies are developed and adopted to improve 
performance. Steps and skills (competences) were qualitatively studied and 
evaluated, and those that are required for practitioners to involve patients in the 
treatment process have been described by (Elwyn et al., 2000, Clyne et al., 2007, 
Stacey et al., 2010) and are identified in eight steps, as shown in Table 1.1   
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Table 1.1 Competency framework for shared decision-making (Simmons et al., 
2010) 
 Competencies  
1 Develop a partnership with the patient 
2 Establish or review the patient‘s preference for information (e.g., amount and 
format of information) 
3 Establish or review the patient‘s preferences for their roles in decision-
making 
4 Ascertain and respond to the patient‘s ideas, concerns, and expectations 
5 Identify the choices and evaluate the research evidence in relation to the 
individual patient 
6 Present (or direct to) evidence, taking into account the above steps, and help 
the patient reflect upon and assess the effect of alternative decisions with 
regard to their values and lifestyles 
7 Make or negotiate a decision in partnership and manage conflict 
8 Agree upon an action plan and complete arrangements for follow-up 
 
 
1.11 Patient participation in shared decision making 
Despite all of the efforts to involve patients in SDM, the main factor in adopting 
shared decision-making into practice still resides in the willingness of the patient to 
participate. However, encouragingly, approximately 40 % of patients are willing to 
participate in the process of SDM regarding medications and treatment. These 
patients are usually more educated and from a younger age group (Deber, 1994, 
Marques et al., 2012). Moreover, it has been found that patients suffering from 
depressive disorders are more willing to participate compared to patients with 
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hypertension, cardiac patients and diabetic patients (Arora and McHorney, 2000, 
Marques et al., 2012). 
1.12 Decision aids  
Patient decision aids have been developed to facilitate and support shared decision-
making between the healthcare professional and the patient. Moreover, psychiatric 
patients must utilize decision aids more than patients with chronic diseases because 
psychiatric patients may face stigma associated with the treatment, delayed onset of 
action, have higher risks of side effects, and have choices between two or more 
alternatives to address their health problem (O‘connor et al., 2004, O‘Connor et al., 
2007, Stacey et al., 2011). 
These decision aids can be in the form of software, web applications, leaflets and 
structured counselling. A review of 55 randomized controlled studies found that 
decision aids improved participation in SDM more than standard counselling 
(O‘Connor et al., 2009). Moreover, there is no evidence that decision aids increase 
the demand for expensive treatments (O‘Connor et al., 2007). The best method is to 
provide both the healthcare provider and the patient with the same information and 
provide each with additional information if required, which is tailored according to 
their individual needs. The provision of information is crucial to be involved in the 
decision making process and may be required to reassure a patient‘s decisions. It can 
support all types of involvement in the decision-making process: active, collaborative 
and passive (O‘Connor et al., 2007, Sheridan et al., 2006, Simmons et al., 2010). 
Most decision aids share the following characteristics (O‘Connor et al., 2007): 
 Provide facts about the medical condition, treatment options and outcomes.  
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  Clarify the treatment outcomes that are most important to the patient.   
 Guide and educate the patient so that a treatment selection can be made. 
 
1.13 Factors influencing shared decision-making 
There have been some factors that influence and accelerate the process of SDM, such 
as (Towle and Godolphin, 1999, Young et al., 2008):  
 Applying real partnerships between healthcare professionals and patients. 
 Type of healthcare system policies. 
 Patients‘ ability to access more information related to treatment options.  
 Use of decision aids to facilitate SDM. 
 Accessibility of health services to patients.  
 
 1.14 Barriers in the implementation of shared decision-making 
There are some barriers to the successful implementation of SDM in clinical practice. 
These barriers include negative attitudes of healthcare professionals, time pressure, 
lack of skills, inability to apply the concept because of the patient‘s characteristics, 
and the clinical setting. The motivation of health professionals and their perception 
that shared decision-making will improve the outcome of the treatment is crucial in 
the removal of barriers to implement SDM (Gravel et al., 2006, Légaré et al., 2008). 
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 1.15 Intervention design according to shared decision-making 
There are three types of approaches to improve a patient‘s participation in SDM 
(Simon et al., 2007):  
 The education and training of health professionals so that they can interact and 
communicate with the patients effectively and improve their participation.  
 The use of decision aids to achieve better adherence to medication, patients‘ 
satisfaction with treatment, less conflict with health professionals, and realistic 
expectations for the treatment.  
 Education of the patients and encouraging them to ask more questions during 
consultations and play an active role in shared decision making. This will make 
the patients realize that they are playing an important role in decision-making 
and will improve adherence and the success rate of treatment. 
1.16 Theoretical explanation for medication adherence 
 Adherence to medication is a contentious decision making process, and a positive 
association has been reported between patients‘ beliefs and adherence to medication 
(Clifford et al., 2008). A review of the literature found several hypotheses about the 
relationship between patients‘ beliefs and decision-making. The authors of these 
studies attempted to explain the change in patient behaviour and how this can be 
applied in clinical practice to change patient behaviour related to health decision 
making. The most important and commonly used theories in explaining the 
relationship between patients‘ beliefs and behaviours, particularly in terms of 
adherence decision making, are as follows (Munro et al., 2007):  
Rosenstock (1966b) proposed the health belief model (HBM) to explain and predict 
health-related behaviour from patterns of belief related to ―the recommended health 
behaviour‖ and ―the health problems‖ (Rosenstock, 1966a). Ajzen and Fishbein have 
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proposed the theory of planned behaviour (TPB) (Fishbein and Ajzen, 1975, 
Prochaska, 2013), which is an extension of the theory of reasoned behaviour (TRA) 
that includes perceptions of behavioural control as predictors of behavioural 
intentions and behaviour (Fishbein and Ajzen, 1975). Such models are often used to 
examine the determinants of behavioural decision making and to predict a variety of 
behaviours. Focusing on the intention to perform the behaviour, TRA suggests that 
attitude and behaviour mainly reflects voluntary behaviour, whereas TPB is used to 
predict human behaviour that can be deliberated and planned (Munro et al., 2007). In 
addition, Prochaska and DiClemente (1983) have proposed the theory of trans-
theoretical model (TTM) (Prochaska, 2013) to explain and predict the five stages of 
change (the phases people go through) that individuals use to change their troubled 
behaviour: pre-contemplation, contemplation, preparation, action, and maintenance. 
This model advocates that an appropriate and successful intervention can only be 
implemented when the stage an individual is at has been determined.  
Several models of health belief do in fact exist. Moreover, several attempt have been 
made to devise interventions based on these models. For example the Fuzzy Trace 
Theory (FTT) has been applied to health and medical decision making in conditions 
such as HIV prevention, surgical risk assessment, cancer prevention and smoking 
cessation (Reyna, 2008). The FTT assumes that intuitive processing is more 
sophisticated and more capable of making decisions that are in context and that 
intuitive processing will lead to increased experience and cognitive development, 
which is associated with increasing reliance on gist processing (as one of memory 
classification by fuzzy trace theory verbatim and gist) (Reyna and Brainerd, 1995, 
Reyna, 2008). In addition, Rob Horne proposed a theoretical model to predict 
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patients‘ beliefs and attitudes to explain patient behaviour. This model identified a 
balance between a patients‘ perceived need for treatment (necessity) and their 
concerns regarding the harmful effects of the medication; this model suggested a 
four-fold classification of patients according to their attitudes towards 
antidepressants (Horne et al., 1999, Tibaldi et al., 2009). There are, however, some 
criticisms regarding these models and their application in the real world to enhance 
adherence (Munro et al., 2007). Nonetheless, these models help describe medication 
taking behaviours and play roles in designing new interventions to enhance 
medication taking behaviours. Further investigation and research is necessary to 
determine which models are suitable to enhance medication taking behaviours in 
chronic diseases. 
 
1.17 Patient beliefs about antidepressants and adherence 
Patients‘ beliefs and concerns about medicine play an important role in adherence to 
medication (Horne et al., 1999). Patients who believe that taking their medications is 
necessary for good health adhere to their medication strictly whereas patients who 
have concerns about taking medication display non-adherence to their medication 
(Horne et al., 1999). Studies of patients with renal disease, asthma, diabetes, cancer, 
coronary heart disease, hypertension, HIV/AIDS, haemophilia, and depression have 
reported an association between low adherence to medication and patient beliefs 
towards the need for medication and concerns about potential adverse effects (Horne, 
2006). 
Patients have their own set of beliefs and views about medication regarding the 
necessity of taking medicine, the method of taking medicine, and the timing or 
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quantity of dosage. These beliefs and views are based on their past experience, 
knowledge, word of mouth from friends and family, their own personal judgement 
about the nature of symptoms or what is suitable for their lifestyle (Tibaldi et al., 
2009).  
Low adherence to medication in patients with bipolar disorder was related to the 
patients‘ beliefs about the need for treatment and strong concerns about potential side 
effects (Clatworthy et al., 2009). Similarly, it has been shown that patient‘s 
adherence to antidepressants depended on their perceived need for treatment 
(necessity) and concerns about harmful effects of the medication (Clifford et al., 
2008). Knowledge of and attitudes towards depression and its treatment may have a 
significant effect on adherence to antidepressants (Gabriel and Violato, 2010). For 
antidepressant medication, ―necessity-minus-concerns‖ is strongly related to the 
adherence rate: patients reported high adherence when necessity exceeded concerns 
and low adherence when concerns exceeded necessity.  
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1.18 Research problems  
Non-adherence to antidepressants is a common challenge in clinical practice because 
of the nature and severity of symptoms of the disease and the characteristics of some 
pharmacological treatments used (e.g., medications that require up to one month until 
the patients feel their condition/symptoms resolved, serious adverse effects, etc.). 
Moreover, the recurrence of disease, relapse and serious complications can result 
from non-adherence to medication. Until now, few published papers regarding 
shared decision making and medication adherence amongst depressed patients have 
been reported in the Saudi Arabia context. 
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1.19 Justification of the study 
 The literature has reported different pharmacist interventions targeting adherence to 
antidepressants using several strategies. However, there is a lack of published studies 
that evaluate the effects of pharmacist interventions using shared decision-making. 
Although research on shared decision-making has displayed promising results 
regarding outcomes in depressed patients, few studies have examined patient 
participation in depression treatment decisions, in contrast to other diseases that have 
been extensively studied (Perestelo-Perez et al., 2011). 
Although it is useful to learn from studies in the literature that were conducted in 
other countries regarding this topic, their findings cannot be extrapolated to the Saudi 
healthcare system because there are differences between the healthcare systems in 
terms of socioeconomic status, culture, lifestyle habits, and spiritual belief towards 
psychiatric diseases (Alsolami et al., 2012, Griffiths et al., 2005, Koenig et al., 2012). 
Although pharmacists have been shown to be beneficial for improving treatment 
outcomes in a variety of healthcare settings, the evaluation of new pharmacist 
approaches to enhance adherence to antidepressants will provide new data that will 
be valuable for health authorities and policy makers. The role of a pharmacist in this 
study is defined as a drug expert amongst the healthcare team who is responsible for 
applying shared decision making interventions regarding the use of medication as a 
part of direct patient care, which is the responsibility of the pharmacist in psychiatric 
hospitals (Santschi et al., 2011). 
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1.20 Importance of the study 
Evidence has shown poor adherence to antidepressant medication amongst patients 
diagnosed with major depressive disorder. Moreover, there is a paucity of data in 
Saudi Arabia regarding adherence to medication (Al-Omran et al., 2000). In 
particular, after conducting an extensive literature search, we identified no studies 
that were conducted to address adherence to antidepressants in Saudi Arabia. 
Therefore, it is important to conduct this research project to provide healthcare 
providers with useful information about patient ‎medication behaviour amongst 
depressed patients in Saudi Arabia. 
Insufficiently treated depression may lead to serious complications such as relapse 
and drug resistance; additionally, there may be pharmacoeconomic consequences and 
impairment in daily functioning (Hunot et al., 2007), which may lead to increased 
rates of morbidity and mortality (Demyttenaere and Haddad, 2000, Jannadi et al., 
2008, Julius et al., 2009).   
However, the adherence of patients with chronic disease to their medications results 
in lower disease-related medical costs and lower hospitalization rates (Sokol et al., 
2005). In the same context, patients‘ adherence to antidepressants results in lower 
total healthcare costs. Adherence to antidepressant therapy has been shown to 
improve economic ‎outcomes (White et al., 2003). Moreover, the literature suggests 
that when depressed patients adhere to their antidepressant medication, their 
adherence to other medications used to treat other ‎medical conditions also improves 
(Katon et al., 2005)‎. 
